Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development
Centessa Pharmaceuticals Plc
Eisai Co Ltd
Idorsia Pharmaceutical Ltd
Inexia Ltd
Johnson & Johnson
Merck & Co Inc
NLS Pharmaceutics AG
Sumitomo Pharma Co Ltd
Synchronicity Pharma Inc
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Yangtze River Pharmaceutical Group
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles
ALKS-2680 - Drug Profile
Product Description
Mechanism Of Action
History of Events
davorexton - Drug Profile
Product Description
Mechanism Of Action
History of Events
daridorexant hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
DSP-0187 - Drug Profile
Product Description
Mechanism Of Action
History of Events
lemborexant - Drug Profile
Product Description
Mechanism Of Action
History of Events
mazindol ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
OPN-021 - Drug Profile
Product Description
Mechanism Of Action
OX2 agonist - Drug Profile
Product Description
Mechanism Of Action
History of Events
OX2 agonist (Oral) - Drug Profile
Product Description
Mechanism Of Action
History of Events
Peptides to Agonize Orexin 2 Receptor for rcolepsy and Unspecified Neurologic Disorders - Drug Profile
Product Description
Mechanism Of Action
History of Events
seltorexant - Drug Profile
Product Description
Mechanism Of Action
History of Events
suvorexant - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-861 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TAK-994 - Drug Profile
Product Description
Mechanism Of Action
History of Events
TS-142 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YNT-185 - Drug Profile
Product Description
Mechanism Of Action
History of Events
YZJ-1139 - Drug Profile
Product Description
Mechanism Of Action
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones
Featured News & Press Releases
Jul 21, 2022: NLS pharmaceutics announces positive opinion from European Regulators to grant Orphan Drug Desigtion for Mazindol ER in idiopathic hypersomnia
Jul 19, 2022: Idorsia announces World Champion Skier, Philanthropist and Entrepreneur Lindsey Vonn as patient ambassador for QUVIVIQ (daridorexant), a Once Nightly Treatment for Insomnia
Jun 03, 2022: Eisai to present latest data on lemborexant at the 36th Annual SLEEP 2022 Meeting
Jun 02, 2022: NLS Pharmaceutics announces over enrollment in its phase 2a clinical trial evaluating Quilience(R) for the treatment of rcolepsy
May 13, 2022: Idorsia U.S. announces first wave of patients prescribed QUVIVIQ (daridorexant) through partnership with pharmacy services provider
May 04, 2022: NLS Pharmaceutics achieves 90% enrollment milestone in Quilience phase 2a clinical trial for patients with rcolepsy
May 03, 2022: Europe’s first dual orexin receptor antagonist - QUVIVIQ (daridorexant) - granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder
May 02, 2022: Idorsia’s new treatment QUVIVIQ (daridorexant) is now available in the US for adults living with insomnia
Mar 28, 2022: NLS Pharmaceutics announces Early Access Program (EAP) allowing patients with idiopathic hypersomnia to receive treatment with Mazindol ER
Mar 16, 2022: NLS Pharmaceutics announces positive interim top-line data for Quilience(R) (Mazindol ER) in Patients with rcolepsy
Mar 10, 2022: New data for daridorexant in patients with insomnia disorder - including long-term safety and efficacy - to be presented at World Sleep 2022
Feb 25, 2022: QUVIVIQ (daridorexant) recommended for approval in Europe as a new treatment for adults with insomnia disorder
Feb 07, 2022: NLS Pharmaceutics to present interim top-line data for Quilience (Mazindol ER) in patients with rcolepsy at the World Sleep Congress in March 2022
Jan 20, 2022: The Lancet Neurology reports impact of daridorexant on both nighttime symptoms and daytime functioning in adults with insomnia
Jan 10, 2022: Idorsia receives US FDA approval of QUVIVIQ (daridorexant) 25 and 50 mg for the treatment of adults with insomnia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Centessa Pharmaceuticals Plc, 2022
Pipeline by Eisai Co Ltd, 2022
Pipeline by Idorsia Pharmaceutical Ltd, 2022
Pipeline by Inexia Ltd, 2022
Pipeline by Johnson & Johnson, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by NLS Pharmaceutics AG, 2022
Pipeline by Sumitomo Pharma Co Ltd, 2022
Pipeline by Synchronicity Pharma Inc, 2022
Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Pipeline by Yangtze River Pharmaceutical Group, 2022
Dormant Products, 2022
Discontinued Products, 2022